Download PDF

1. Company Snapshot

1.a. Company Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.


The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial.Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc.The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Show Full description

1.b. Last Insights on CYTK

Cytokinetics' recent performance was negatively impacted by a wider-than-expected Q4 loss, driven by rising expenses. The company's quarterly loss of $1.5 per share exceeded the Zacks Consensus Estimate of $1.48. Despite the FDA approval of Myqorzo for adults with symptomatic obstructive HCM in the US, China, and Europe, the stock faced challenges. Additionally, investigations by law firms, including The Law Offices of Frank R. Cruz and Grabar Law Office, into potential breaches of fiduciary duties by the company's board of directors may have added uncertainty.

1.c. Company Highlights

2. Cytokinetics' MYCorzo Launch and Pipeline Advancements Drive Growth

Cytokinetics, Incorporated reported a net loss of $183 million, or $1.50 per share, for Q4 2025, compared to a net loss of $150 million, or $1.26 per share, in Q4 2024. Total revenues in Q4 2025 were $17.8 million, and total revenues for the full year 2025 were $88 million. The actual EPS came in at -$1.5, slightly worse than estimates of -$1.48. Research and development expenses for Q4 2025 were $104.4 million, up from $93.6 million in Q4 2024, driven by advancing clinical trials and higher personnel costs.

Publication Date: Feb -25

📋 Highlights
  • FDA & Global Approvals:: MYCorzo approved in the US, China, and with CHMP positive opinion in the EU, marking 2025 as a pivotal year for Cytokinetics.
  • Commercial Launch Momentum:: Immediate US launch post-FDA approval, achieving 700+ REMS-certified HCPs in 3 weeks and 12,000+ customer engagements within the first quarter.
  • Financial Performance:: Ended 2025 with $1.22B cash, but Q4 net loss rose to $183M ($1.50/share) vs. $150M ($1.26/share) in 2024, driven by R&D ($416M) and G&A ($284.3M) expenses.
  • ACACIA-HCM Trial Outlook:: Pivotal Phase 3 results expected Q2 2026, targeting statistical significance on KCCQ or peak VO2 endpoints with 90% power and 10% discontinuation rate.

Commercial Launch of MYCorzo

The company has made significant progress in the commercial launch of MYCorzo, with over 700 healthcare professionals REMS-certified within three weeks of approval. According to Andrew M. Callos, EVP and Chief Commercial Officer, the company has achieved over 12,000 customer engagements and is seeing strong demand from cardiologists and patients. The company's early market uptake is in line with expectations, driven by demand from cardiologists and patients who were awaiting approval.

Pipeline Advancements

Cytokinetics is advancing its pipeline, with the ACACIA-HCM trial expected to report top-line results in Q2 2026. Fady Malik, EVP of R&D, noted that the study is designed to demonstrate a five-point delta on KCCQ and a peak VO2 of 1, with 90% power to detect statistically significant differences. The company is also conducting the COMMUN-HF and AMBER-HFpEF clinical trials, and is on track to share results from these trials in the coming quarters.

Financial Guidance

The company expects GAAP combined R&D and SG&A expenses to be between $830 million and $870 million in 2026, with stock-based compensation expected to be between $120 million and $130 million. Cytokinetics finished 2025 with approximately $1.22 billion in cash, cash equivalents, and investments, providing a strong foundation for the company's growth plans.

Valuation

With analysts estimating next year's revenue growth at 226.1%, the company's valuation multiples are worth examining. The P/S Ratio is 98.28, indicating a high valuation relative to sales. The EV/EBITDA ratio is -14.77, reflecting the company's negative earnings. As the company advances its pipeline and launches MYCorzo in new markets, investors will be watching for progress on revenue growth and profitability.

3. NewsRoom

Card image cap

Cytokinetics to Participate in March Investor Conferences

Mar -02

Source: globenewswire.com

Card image cap

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans

Feb -25

Source: zacks.com

Card image cap

Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript

Feb -25

Source: seekingalpha.com

Card image cap

Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

Feb -25

Source: zacks.com

Card image cap

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Feb -24

Source: globenewswire.com

Card image cap

Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo

Feb -18

Source: zacks.com

Card image cap

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Feb -17

Source: globenewswire.com

Card image cap

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Feb -12

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Muscle Activators

Expected Growth: 9.27%

Cytokinetics' Muscle Activators, with 9.27% growth, is driven by increasing adoption in rare muscle disorders, strong clinical trial results, and expanding partnerships. Growing demand for novel treatments in neuromuscular diseases, such as spinal muscular atrophy and amyotrophic lateral sclerosis, also contributes to this growth.

7. Detailed Products

Omnecartil

Omnecartil is a cardiac myosin activator that increases cardiac contractility and is being developed for the treatment of heart failure.

CK-3773274

CK-3773274 is a next-generation cardiac myosin inhibitor that reduces cardiac contractility and is being developed for the treatment of hypertrophic cardiomyopathy (HCM).

CK-274

CK-274 is a cardiac myosin inhibitor that reduces cardiac contractility and is being developed for the treatment of hypertrophic cardiomyopathy (HCM).

CK-136

CK-136 is a cardiac troponin activator that increases cardiac contractility and is being developed for the treatment of heart failure.

CK-107

CK-107 is a fast skeletal muscle troponin activator that increases muscle force and is being developed for the treatment of spinal muscular atrophy (SMA) and other neuromuscular diseases.

8. Cytokinetics, Incorporated's Porter Forces

Forces Ranking

Threat Of Substitutes

Cytokinetics, Incorporated has a moderate threat of substitutes due to the availability of alternative treatments for cardiovascular and muscle disorders.

Bargaining Power Of Customers

Cytokinetics, Incorporated has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective treatments.

Bargaining Power Of Suppliers

Cytokinetics, Incorporated has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and the company's dependence on a few key suppliers.

Threat Of New Entrants

Cytokinetics, Incorporated has a high threat of new entrants due to the attractiveness of the pharmaceutical industry and the ease of entry for new companies with innovative technologies.

Intensity Of Rivalry

Cytokinetics, Incorporated operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among companies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 255.14%
Debt Cost 7.56%
Equity Weight -155.14%
Equity Cost 7.56%
WACC 7.56%
Leverage -164.46%

11. Quality Control: Cytokinetics, Incorporated passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
BioMarin Pharmaceutical

A-Score: 4.8/10

Value: 5.0

Growth: 8.4

Quality: 8.0

Yield: 0.0

Momentum: 1.5

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
SpringWorks Therapeutics

A-Score: 4.3/10

Value: 6.2

Growth: 4.6

Quality: 5.0

Yield: 0.0

Momentum: 8.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Cytokinetics

A-Score: 4.0/10

Value: 8.0

Growth: 0.4

Quality: 4.9

Yield: 0.0

Momentum: 9.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Sarepta Therapeutics

A-Score: 3.8/10

Value: 8.7

Growth: 7.9

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Agios Pharmaceuticals

A-Score: 3.2/10

Value: 7.6

Growth: 4.2

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Crinetics Pharmaceuticals

A-Score: 2.8/10

Value: 6.4

Growth: 1.1

Quality: 5.1

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

60.72$

Current Price

60.72$

Potential

-0.00%

Expected Cash-Flows